Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

[Clinico-pathological conference report: sudden deterioration of general condition, hypokalemia and diabetes in an elderly man].

Metso S, Arola J, Raade M, Välimäki M.

Duodecim. 2012;128(14):1487-96. Finnish.

PMID:
22937608
2.

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.

Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T; Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.

J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.

PMID:
18635218
4.

Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.

Laufer M, Sinibaldi VJ, Carducci MA, Eisenberger MA.

Urology. 1999 Oct;54(4):745.

PMID:
10754148
5.

A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.

Lau YK, Chadha MK, Litwin A, Trump DL.

J Hematol Oncol. 2008 Nov 5;1:21. doi: 10.1186/1756-8722-1-21.

6.

Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.

Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.

Int J Urol. 2007 Mar;14(3):264-7.

7.

Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.

Okegawa T, Nutahara K, Higashihara E.

Int J Urol. 2010 Nov;17(11):950-5. doi: 10.1111/j.1442-2042.2010.02620.x.

8.

Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study.

Cussenot O, Cornu JN, Drouin SJ, Mozer P, Egrot C, Vaessen C, Haab F, Bitker MO, Rouprêt M.

World J Urol. 2014 Apr;32(2):545-50. doi: 10.1007/s00345-013-1196-y. Epub 2013 Oct 29.

PMID:
24166289
11.

Prostate-specific antigen-all that rises is not refractory.

Hintz BL, Van Nieuwenhuize A, Kagan AR.

Urology. 2001 May;57(5):975.

PMID:
11337308
12.

[Disseminated carcinomatosis of the bone marrow in two patients with prostate cancer].

Kato T, Yamamoto N, Matsuoka Y, Kuwata Y, Taoka T, Kazuki N, Kushida Y, Kakehi Y.

Nihon Hinyokika Gakkai Zasshi. 2011 Jan;102(1):28-33. Japanese.

PMID:
21520634
13.

[Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].

Barbón JJ, González-Tuero J, Gay LL, Pérez-García FJ, Sampedro A.

Arch Soc Esp Oftalmol. 2007 Nov;82(11):715-7. Spanish.

14.

Comment on "secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study".

de la Taille A.

World J Urol. 2014 Dec;32(6):1625-6. doi: 10.1007/s00345-013-1234-9. Epub 2014 Jan 11. No abstract available.

PMID:
24413818
15.

Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.

Kanesvaran R, Phipps C, Cheng CW, Chan MM, Khoo D, Tan MH.

Ann Acad Med Singapore. 2010 Jul;39(7):580-2. No abstract available.

16.

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.

Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ.

J Urol. 1998 Jan;159(1):149-53.

PMID:
9400459
17.

Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy.

Todd NF, Lieberman R, Gulley JL, Dahut W, Arlen PM.

Am J Ther. 2005 Mar-Apr;12(2):172-4.

PMID:
15767834
18.

Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.

Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. doi: 10.1016/j.ijrobp.2008.10.071. Epub 2009 Mar 14.

PMID:
19289266
19.

Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.

Lodde M, Lacombe L, Fradet Y.

Urology. 2010 Nov;76(5):1189-93. doi: 10.1016/j.urology.2009.12.057. Epub 2010 Mar 29.

PMID:
20303155
20.

Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.

Solberg A, Haugen OA, Viset T, Bergh A, Tasdemir I, Ahlgren G, Widmark A, Angelsen A.

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):55-61. doi: 10.1016/j.ijrobp.2010.01.072.

PMID:
20598453
Items per page

Supplemental Content

Write to the Help Desk